drugset / Trial / NCT05282719
Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
NaSingle-groupOpen-labelPrevention
Summary
To explore the efficacy of venetoclax combined with azacytidine in Myelodysplastic / myeloproliferative neoplasms（MDS/MPN）, so as to improve the overall survival and treatment status of MDS/MPN patients.
Timeline
- Start
- 2022-04
- Primary completion
- 2022-08
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Decitabine | Small molecule | 75 mg/m2 | Subcutaneous |
| Subject | Venetoclax | Small molecule | 400 mg | — |